Evaluate your Novel Immuno-Oncology Agents with our Wide Range of Validated Models
Immunotherapy represents the most promising new cancer treatment approach since the first development of chemotherapies, and has come of age with multiple recent approvals for checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents across a range of cancer types.
In this diverse therapeutic area, CrownBio understands that one in vivo model will not meet all reseach needs, and we have therefore developed a wide ranging In Vivo Immunotherapy Translational Technology Platform providing a variety of model types for preclinical evaluation.
CAR-T Therapy Evaluation
Evaluate your CAR-T therapies using either:
- our extensive collection of 2,500 HuPrime® Patient-Derived Xenograft (PDX) models in immuno-compromised or partially compromised mice
- our validated CD19-targeting Cell Line Derived Xenograft Model
- Hematopoietic stem cell (HSC) PDX models harness the human immune system against human tumors (combining humanized mice with our HuPrime PDX models) providing a robust in vivo platform for evaluation and efficacy testing of potential new immunotherapeutics
- The MiXeno platform of transient human immunity in mice provides a simple alternative to the full stem cell reconstitution approach, for a variety of immuno-oncology applications including:
- BiTE®-like antibodies, checkpoint inhibitor assessment, antibody-dependent cellular cytotoxicity (ADCC) effects testing, and NK modulating agent evaluation
- HuGEMM™ and HuCELL™ unique models express humanized drug targets in a fully functional murine immune system to evaluate human-specific biological therapies
- models for PD-1, CTLA-4, and PD-L1 currently validated and many more models in development
HuGEMM HuCTLA-4 Model Tumor Growth Inhibition Following Anti-hCTLA-4 Treatment
Murine Efficacy/PD Models
MuPrime™ murine allograft models derived from GEMM or carcinogen-induced models combine:
- the improved predictive power of their parental models
- with an operational simplicity, consistency, and robust growth
- for pharmacology research, including in vivo efficacy and PD assessment
Contact us today for free expert advice on choosing the right immuno-oncology model to fit your research needs.